Viewing a single comment thread. View all comments

SaltZookeepergame691 t1_jdbrkvk wrote

Not an oncologist, but it’s far too early to tell. They saw no tumour responses, and the length of response in a couple of patients could easily just be chance.

They are now running a (single arm) trial in patients with platinum sensitive ovarian cancer in conjunction with platinum chemotherapy, so they clearly see this as an adjunctive therapy. But as said elsewhere, there is a huge way to go from phase 1 to rolling out an actually effective drug that provides net benefits to patients.